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Echocardiography is widely used in both patient care and
clinical research because of its entirely noninvasive nature,
versatility, availability, portability, and suitability for serial
studies. In clinical trials, echocardiography is used to
determine study enrollment eligibility, to measure surrogate
endpoints, and to provide insights into the natural history
and mechanisms of disease and therapeutic efﬁcacy. How-
ever, the acquisition and interpretation of echocardiograp-
hic data is highly patient- and operator-dependent, which
introduces variability and bias and lowers reproducibility.See page 2514In addition to this performance-based variation that inﬂu-
ences data acquisition, inconsistency of echocardiographic
data may be due to biological (e.g., beat to beat) and
interpretative (e.g., intra- and interobserver, test-retest)
variability, and in the case of serial studies, regression to
the mean (1). A widely cited example of a large clinical trial
that was derailed because of poor limits of agreement and
reproducibly of echocardiographic data is the PROSPECT
(Predictors of Response to Cardiac Resynchronization
Therapy) trial (2,3). Recognizing the need to limit variability
of cardiac ultrasound in clinical trials, the American Society
of Echocardiography published recommendations that pro-
moted the use of core (i.e., centralized) laboratories and
outlined speciﬁc quality control measures and echocardio-
graphic reading strategies (4).
Supporting the intuitive advantages of a core laboratory
(e.g., hands-on training at local sites, using a limited number
of experienced observers, monitoring reader variability,*Editorials published in the Journal of the American College of Cardiology reﬂect the
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American College of Cardiology.
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that have shown that a core laboratory can minimize vari-
ability (5,6). Indeed, because of a reduction of random errors
that resulted in reduced measurement variability, measure-
ments of left ventricular volume made at a core laboratory,
but not at local participating sites, were able to predict
nonfatal heart failure events in a multicenter, serial study of
remodeling after myocardial infarction (6). Minimizing
variability is also critical for the efﬁciency of a trial: that is,
the sample size needed to detect a signiﬁcant difference
thereby inﬂuences the cost and duration of a trial. These
potential beneﬁts are thought to overcome the increased cost
and complexity of a clinical study that employs a core lab (7).
In this regard, in this issue of the Journal, Hahn et al. (8)
present the centrally adjudicated echocardiographic core
laboratory data from the PARTNER (Placement of Aortic
Transcatheter Valves) Cohort A study, which randomized
699 high-risk patients with severe aortic stenosis to either
surgical aortic valve replacement (SAVR) or transcatheter
aortic valve replacement (TAVR).
TAVR has rapidly become the accepted treatment option
for inoperable patients and a viable alternative to surgical
valve replacement (SAVR) in high-risk patients with severe
aortic stenosis (9,10). However, the variability reported in
trials is considerable, as the majority of studies of TAVR are
single-center, nonrandomized, or registries, many of which
lack standardization and precise deﬁnitions, use various sizes
and types of valves, and are performed by operators with
variable experience. For example, the range of reported
incidences of paravalvular regurgitation after TAVR is wide
(50% to 85% overall, mild in 7.8% to 40.8%, moderate in 5%
to 37.9%, and severe in 0.5% to 13.6%) (11). In these
instances, variability was further compounded by differences
in the imaging modalities and regurgitant severity scales
used, the timing of the post-procedural assessment, and the
adjudication of events. These are study design ills for which
the core laboratory may be partly curative. In this context,
the study by Hahn et al. (8) is particularly relevant. Using an
“as-treated” analysis, rather than an intent-to-treat analysis
(as was used in the published trial [12]), the investigators
compare 326 TAVR and 311 SAVR at baseline and post-
procedurally at discharge, 30 days, 6 months, and 1 and
2 years. For analysis, the “ﬁrst post-implantation values”
were taken from the ﬁrst available value from echocardio-
grams obtained at discharge, 30 days, or 6 months. The
investigators report immediate and sustained improvements
in aortic gradients and effective oriﬁce area (EOA) in both
cohorts. Compared with SAVR, TAVR resulted in larger
EOA and less prosthesis-patient mismatch (PPM), but
consistent with other studies (13), more aortic insufﬁciency
(total and paravalvular). Thus, the type of aortic valve
replacement had important, but not entirely predictable,
structural and functional consequences. Whereas a larger
EOA and less PPM might be expected to favorably inﬂu-
ence prognosis, it is disappointing to note that mild or
greater post-procedural aortic regurgitation predicted 1-year
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2523mortality in European registries (14–16) and in the follow-
up results of the Cohort A of the PARTNER trial (12). A
critical unanswered question is whether paravalvular aortic
insufﬁciency (AI) itself is responsible for the poor short-
and long-term prognosis or if paravalvular AI is merely a
marker for other unrecognized factors. Though not directly
addressing this question, the study by Hahn et al. does
provide important insights into this complication by a
rigorous analysis of baseline and post-procedural echo
characteristics and outcomes associated with paravalvular AI.
TAVR patients with mild or greater prosthetic regurgi-
tation had at baseline, larger left ventricular (LV) and aortic
annular dimensions, and lesser ejection fraction and stroke
volume than patients with less than mild prosthetic regur-
gitation; after implantation, they had larger LV dimensions
and mass, higher stroke volume, and importantly, a lower
cover index (a surrogate for prosthetic-annulus incongruence
or mismatch). These data are consistent with studies that
demonstrate that larger aortic annulus size on magnetic
resonance imaging and computed tomography predicts
paravalvular AI (17). In contrast, there were no baseline
clinical characteristics that distinguished between these
2 groups, suggesting that in cases of clinical equipoise,
echocardiography may have a role in selecting the better
method (i.e., TAVR or SAVR) for aortic valve replacement.
The echocardiographic variables after implantation that
were univariate predictors of death after TAVR were mild
or greater prosthetic regurgitation, increased LV diastolic
volume, decreased ejection fraction, and somewhat coun-
terintuitively, larger EOA and less PPM (whereas those for
SAVR were not surprisingly smaller LV volumes, decreased
stroke volume, smaller EOA, and increased PPM). These
data suggest that the paradoxically adverse effects of a greater
EOA and lesser PPM after TAVR in this study reﬂect the
impact of a larger annular size instigating (and the increased
stroke volume resulting from) aortic regurgitation. Impor-
tantly, the mild degree of paravalvular leak seen in this study
would not be expected to have such an adverse inﬂuence on
prognosis. However, this may be due to an underestimation
of regurgitant severity because despite the use of an inte-
grative approach and Valve Academic Research Consortium
criteria (18,19), precise quantitation of regurgitant severity is
challenging at best (16,20). Whether additional independent
and poorly understood variables are responsible is an
important direction for future research.
The causes of paravalvular leak include: inappropriate
sizing and malapposition of the prosthesis; the extent and
location of aortic calcium, which may result in an incomplete
seal between the prosthesis and the aorta; a large aortic
annulus; and a low pre-procedural cover index (suggesting
prosthetic undersizing) (15). In view of the short- and long-
term prognostic importance of post-procedural paravalvular
leak, complementary approaches to assess its severity and
its effects on outcomes are warranted. For example, the
aortic regurgitation index (the ratio of the gradient between
aortic diastolic pressure and LV end-diastolic pressure tosystolic blood pressure) decreased with increasing severity of
aortic regurgitation and predicted the 1-year mortality after
transcatheter aortic valve implantation independent of the
echocardiographic degree of paravalvular leak (21). Thus,
efforts to recognize, quantify, and reduce the incidence of
prosthetic aortic regurgitation are critical.
The limitations of the study (i.e., site-speciﬁc annular
measurements, limited echocardiographic measurability, lack
of adjustment for multiple comparisons, variable times used
for ﬁrst-implantation measurements, difﬁculties quantifying
aortic insufﬁciency, and survivorship bias) are acknowledged
by the investigators. An unavoidable problem worth em-
phasis is the large amount of data that is missing and the
attrition over the 2-year follow-up period, which may lead to
an imbalance between the 2 groups and ﬁndings that are
difﬁcult to explain. For example, LV mass regression was
greater (“more absolute”) in SAVR versus TAVR patients
despite greater PPM in the former. Whether this was due to
aortic insufﬁciency or protocol violations as the investigators
posit or are unanticipated statistical effects of attrition remain
unclear; what is clear is that by the end of the study, there
were no differences in LV size, function, or mass in the
2 groups. Although many of the observations by Hahn et al.
are hypothesis-generating, the study is important because of
its multicenter, randomized design that uses core laboratory
principles to maximize the accuracy and precision of echo-
cardiographic data that are used to identify predictive base-
line and post-procedural echocardiographic variables for
TAVR and SAVR in a high-risk population of patients with
severe aortic stenosis.
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